Johann S de Bono

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers
    Geraldine Perkins
    Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    PLoS ONE 7:e47020. 2012
  2. pmc Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
    A Bahl
    Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
    Ann Oncol 24:2402-8. 2013
  3. pmc The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
    L R Molife
    The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 103:332-9. 2010
  4. pmc First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
    T A Yap
    Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, UK
    Br J Cancer 106:1379-85. 2012
  5. pmc A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
    S P Blagden
    Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 98:894-9. 2008
  6. doi request reprint Targeting cell cycle kinases and kinesins in anticancer drug development
    Timothy A Yap
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Expert Opin Drug Discov 2:539-60. 2007
  7. doi request reprint Interview with Johann de bono for future oncology
    Johann de Bono
    Royal Marsden, NHS Foundation Trust and the Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Future Oncol 8:1381-2. 2012
  8. pmc Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
    Alison H M Reid
    The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    J Clin Oncol 28:1489-95. 2010
  9. pmc Abiraterone and increased survival in metastatic prostate cancer
    Johann S de Bono
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 364:1995-2005. 2011
  10. doi request reprint Translating cancer research into targeted therapeutics
    J S de Bono
    The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Nature 467:543-9. 2010

Detail Information

Publications81

  1. pmc Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers
    Geraldine Perkins
    Division of Clinical Studies, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    PLoS ONE 7:e47020. 2012
    ..Overall, circulating nucleic acid biomarker studies have clinically important multi-purpose utility in advanced cancer patients and further studies to pursue their incorporation into the standard of care are warranted...
  2. pmc Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
    A Bahl
    Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
    Ann Oncol 24:2402-8. 2013
    ..We examined patient survival at 2 years and tumour-related pain with cabazitaxel versus mitoxantrone...
  3. pmc The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
    L R Molife
    The Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 103:332-9. 2010
    ....
  4. pmc First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
    T A Yap
    Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, UK
    Br J Cancer 106:1379-85. 2012
    ..A phase I study was undertaken to investigate safety, dose-limiting toxicities (DLTs), recommended phase II dose (RP2D), pharmacokinetics (PKs) and preliminary antitumour activity of PM00104 as a 1- or 3-h infusion three-weekly...
  5. pmc A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
    S P Blagden
    Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 98:894-9. 2008
    ..The MTD for ispinesib and docetaxel was defined and the combination demonstrated an acceptable toxicity profile. Preliminary PK data suggest no interaction between ispinesib and docetaxel...
  6. doi request reprint Targeting cell cycle kinases and kinesins in anticancer drug development
    Timothy A Yap
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Expert Opin Drug Discov 2:539-60. 2007
    ..Although challenges of potency and non-specificity have hampered their progress through the clinic, several novel compounds are presently in various phases of clinical trial evaluation...
  7. doi request reprint Interview with Johann de bono for future oncology
    Johann de Bono
    Royal Marsden, NHS Foundation Trust and the Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Future Oncol 8:1381-2. 2012
    ..One of these drugs is enzalutamide, which has recently been submitted for European marketing authorization following positive clinical trials...
  8. pmc Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate
    Alison H M Reid
    The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    J Clin Oncol 28:1489-95. 2010
    ..The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC)...
  9. pmc Abiraterone and increased survival in metastatic prostate cancer
    Johann S de Bono
    Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, United Kingdom
    N Engl J Med 364:1995-2005. 2011
    ..We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy...
  10. doi request reprint Translating cancer research into targeted therapeutics
    J S de Bono
    The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Nature 467:543-9. 2010
    ..The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biology of the patient and their cancer...
  11. doi request reprint Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
    J S de Bono
    Drug Development Unit, Royal Marsden Hospital Institute of Cancer Research, Sutton, UK
    Ann Oncol 23:1241-9. 2012
    ..We evaluated eribulin mesylate (E7389), a nontaxane halichondrin B analog microtubule inhibitor, in patients with metastatic CRPC with or without previous taxane exposure...
  12. ncbi request reprint Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor
    Johann S de Bono
    Royal Marsden NHS Foundation Trust, London, United Kingdom
    Clin Cancer Res 13:3611-6. 2007
    ..To detect insulin-like growth factor-IR (IGF-IR) on circulating tumor cells (CTC) as a biomarker in the clinical development of a monoclonal human antibody, CP-751,871, targeting IGF-IR...
  13. doi request reprint Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    Johann Sebastian de Bono
    Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, UK
    Lancet 376:1147-54. 2010
    ..We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment...
  14. pmc Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?
    Timothy A Yap
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    EPMA J 3:3. 2012
    ....
  15. pmc Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer
    Gerhardt Attard
    Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 27:3742-8. 2009
    ..Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis...
  16. ncbi request reprint The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
    Shahneen K Sandhu
    The Institute of Cancer Research, Sutton, Surrey, UK
    Lancet Oncol 14:882-92. 2013
    ..We investigated the safety, tolerability, maximum tolerated dose, pharmacokinetic and pharmacodynamic profiles, and preliminary antitumour activity of niraparib...
  17. pmc First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors
    Andre T Brunetto
    Authors Affiliations Drug Development Unit, Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom and 4SC AG, Planegg Martinsried, Germany
    Clin Cancer Res 19:5494-504. 2013
    ....
  18. doi request reprint Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer
    Gerhardt Attard
    The Institute of Cancer Research, Sutton, Surrey SM2 5PT, UK
    J Clin Endocrinol Metab 97:507-16. 2012
    ..Abiraterone acetate is a small-molecule cytochrome P450 17A1 (CYP17A1) inhibitor that is active in castration-resistant prostate cancer...
  19. ncbi request reprint Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
    David Olmos
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK
    Lancet Oncol 13:1114-24. 2012
    ..We analysed blood mRNA expression arrays to identify patients with metastatic castration-resistant prostate cancer with poorer outcome...
  20. doi request reprint Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies
    David Olmos
    Drug Development Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Downs Road, Sutton, Surrey, United Kingdom
    Clin Cancer Res 17:3420-30. 2011
    ..GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1). A phase I study of two schedules of intravenous GSK461364 was conducted...
  21. ncbi request reprint Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study
    Joo Ern Ang
    Authors Affiliations The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton Edinburgh Cancer Research UK Center, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh The Cancer Research UK Gene Function Laboratory Breakthrough Breast Cancer Research Center Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom University of California San Francisco, San Francisco, California Department of Medical Oncology, Prince of Wales Clinical School, Prince of Wales Hospital, Sydney, Australia The Chaim Sheba Medical Center, Tel Hashomer, Israel Princess Margaret Hospital, Toronto, Canada Oncologisch Centrum Vrije Universiteit Brussel, Brussels, Belgium and Dana Farber Cancer Center, Boston, Massachusetts
    Clin Cancer Res 19:5485-93. 2013
    ..The efficacy of chemotherapy in the PARPi-resistant setting was therefore investigated...
  22. ncbi request reprint Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer
    Gerhardt Attard
    The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 69:2912-8. 2009
    ..007) in CRPC patients treated with abiraterone acetate. These data confirm that CTCs are malignant in origin and indicate that hormone-regulated expression of ERG persists in CRPC...
  23. doi request reprint Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
    Peter C Fong
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, Sutton, Surrey, United Kingdom
    N Engl J Med 361:123-34. 2009
    ..We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor...
  24. doi request reprint Cabazitaxel in metastatic castration-resistant prostate cancer
    Timothy A Yap
    Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK
    Expert Rev Anticancer Ther 12:1129-36. 2012
    ....
  25. doi request reprint Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
    Craig P Carden
    Drug Development Unit, Royal Marsden Hospital, Marsden Hospital, Sutton, Surrey SM2 5PT, UK
    Drug Discov Today 15:88-97. 2010
    ..In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents...
  26. ncbi request reprint Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven
    Gerhardt Attard
    Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 69:4937-40. 2009
    ..Biomarker studies, including the analysis of ETS gene fusion status, on patients treated with abiraterone acetate may allow enrichment of patients with a sensitive phenotype in future studies of therapeutics targeting CYP17...
  27. ncbi request reprint Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
    Peter C Fong
    Drug Development Unit, Royal Marsden National Health Service Foundation Trust, Sutton, Surrey, UK
    J Clin Oncol 28:2512-9. 2010
    ..Platinum-based chemotherapy responses correlate with HR DNA repair capacity. Olaparib is a potent, oral PARP inhibitor that is well tolerated, with antitumor activity in BRCA1/2 mutation carriers...
  28. ncbi request reprint Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development
    Daniel S W Tan
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, UK
    Cancer J 15:406-20. 2009
    ....
  29. doi request reprint Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies
    Timothy A Yap
    Royal Marsden National Health Service Foundation Trust, The Institute of Cancer Research, Sutton, Surrey, UK
    J Clin Oncol 29:1271-9. 2011
    ..A phase I trial of ARQ 197 was conducted to assess safety, tolerability, and target inhibition, including intratumoral c-MET signaling, apoptosis, and angiogenesis...
  30. ncbi request reprint Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
    Alison H M Reid
    The Institute of Cancer Research, Sutton, Surrey, UK
    Mod Pathol 25:902-10. 2012
    ..This observation could explain the absence of PTEN protein expression in a subgroup of tumours previously classified as having heterozygous genomic loss using single-probe traditional FISH assays...
  31. doi request reprint Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials
    David Olmos
    Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK
    Clin Cancer Res 17:5188-96. 2011
    ..We hypothesized that the incorporation of CTC counts might improve patient selection for phase I trials...
  32. ncbi request reprint Targeting the DNA damage response in oncology: past, present and future perspectives
    Bristi Basu
    Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
    Curr Opin Oncol 24:316-24. 2012
    ..We review lessons learnt from the development of inhibitors against DNA damage response mechanisms and envision the future of DNA repair inhibition in oncology...
  33. doi request reprint Molecular pathology and prostate cancer therapeutics: from biology to bedside
    Daniel Nava Rodrigues
    Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK
    J Pathol 232:178-84. 2014
    ..Understanding the molecular aspects of PCa therapeutics will allow pathologists to provide core recommendations for patient management...
  34. doi request reprint The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer
    Craig P Carden
    Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutic, The Institute of Cancer Research, Sutton, United Kingdom
    Mol Cancer Ther 11:1609-17. 2012
    ..There is no clear evidence that this is driven specifically by PIK3CA or AKT mutations or by amplifications or deletion of PTEN...
  35. ncbi request reprint Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer
    Johann S de Bono
    Section of Medicine, Institute of Cancer Research, Royal Marsden Hospital, Downs Road, Sutton, Surrey, United Kingdom
    Clin Cancer Res 14:6302-9. 2008
    ..Secondary objectives included determining the prognostic utility of CTC measurement before initiating therapy, and the relationship of CTC to prostate-specific antigen (PSA) changes and OS at these and other time points...
  36. doi request reprint Therapeutic options for advanced prostate cancer: 2011 update
    Aurelius Omlin
    Drug Development Unit, The Institute of Cancer Research, ICR and Royal Marsden NHS Foundation Trust, Sycamore House, Downs Road, Sutton, Surrey, SM25PT, UK
    Curr Urol Rep 13:170-8. 2012
    ..This review will focus on the recent developments in the field of CRPC...
  37. ncbi request reprint Steroid hormone receptors in prostate cancer: a hard habit to break?
    Gerhardt Attard
    The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Cancer Cell 16:458-62. 2009
    ....
  38. doi request reprint Envisioning the future of early anticancer drug development
    Timothy A Yap
    Drug Development Unit, Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Nat Rev Cancer 10:514-23. 2010
    ..In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs...
  39. doi request reprint Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
    Timothy A Yap
    Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    CA Cancer J Clin 61:31-49. 2011
    ....
  40. ncbi request reprint Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
    Gerhardt Attard
    Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 26:4563-71. 2008
    ..To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued...
  41. ncbi request reprint Targeting CYP17: established and novel approaches in prostate cancer
    Timothy A Yap
    The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK
    Curr Opin Pharmacol 8:449-57. 2008
    ....
  42. ncbi request reprint Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
    Timothy A Yap
    Drug Development Unit, The Royal Marsden National Health Service Foundation Trust, and the Institute of Cancer Research, Sutton, Surrey, United Kingdom
    J Clin Oncol 28:3965-72. 2010
    ..A phase I study of continuous once-daily oral BIBW 2992 was conducted to determine safety, maximum-tolerated dose, pharmacokinetics (PK), food effect, and preliminary antitumor efficacy...
  43. doi request reprint Visceral disease in castration-resistant prostate cancer
    Carmel J Pezaro
    Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK
    Eur Urol 65:270-3. 2014
    ..Visceral metastases are now more commonly detected in men with CRPC, likely due to the introduction of novel survival-prolonging treatments. ..
  44. doi request reprint A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
    Shahneen K Sandhu
    Drug Development Unit, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Cancer Chemother Pharmacol 71:1041-50. 2013
    ..Blocking CCL2 has preclinical antitumor activity. A phase 1 trial of carlumab (CNTO 888), a human anti-CCL2 IgG1κ mAb, was conducted to evaluate the safety, tolerability, pharmacokinetic-pharmacodynamic profile, and antitumor activity...
  45. doi request reprint The changing therapeutic landscape of castration-resistant prostate cancer
    Timothy A Yap
    Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Nat Rev Clin Oncol 8:597-610. 2011
    ..We propose a treatment pathway for patients with CRPC and consider strategies to optimize the use of these agents, including the incorporation of predictive and intermediate end point biomarkers, such as circulating tumor cells...
  46. doi request reprint Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
    Andrew Eichholz
    Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Mol Cell Endocrinol 360:68-75. 2012
    ..Heat shock proteins (HSPs) bind to the androgen receptor and modify its activity. Several HSP inhibitors are under evaluation in clinical trials. This review explores the role of CYP17 inhibitors, MDV3100, and HSP inhibitors...
  47. doi request reprint Management of metastatic castration-resistant prostate cancer: recent advances
    Deborah Mukherji
    Institute of Cancer Research, Sutton, Surrey, UK
    Drugs 72:1011-28. 2012
    ..Optimal methods of treatment selection, combination and sequencing have yet to be determined...
  48. doi request reprint Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective
    Shahneen K Sandhu
    The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom
    Eur J Cancer 46:9-20. 2010
    ..This review outlines the biological function and rationale of targeting PARP, details pre-clinical and clinical data and discusses the promises and challenges involved in developing these antitumour agents...
  49. ncbi request reprint Targeting the PI3K/AKT pathway for the treatment of prostate cancer
    Debashis Sarker
    Section of Medicine and Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, United Kingdom
    Clin Cancer Res 15:4799-805. 2009
    ..In particular, we highlight the importance of the appropriate selection of agents and combinations, and the critical role of predictive and pharmocodynamic biomarkers...
  50. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors
    Johann S de Bono
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Surrey, UK
    Clin Cancer Res 14:6663-73. 2008
    ..To determine the safety, maximum tolerated dose, and pharmacokinetic-pharmacodynamic profile of a histone deacetylase inhibitor, LAQ824, in patients with advanced malignancy...
  51. ncbi request reprint The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment
    Shahneen K Sandhu
    The Royal Marsden NHS Foundation Trust, Downs Road Sutton, Surrey, UK
    Curr Drug Targets 12:2034-44. 2011
    ..This review discusses the rationale for targeting PARP and details the strategies and challenges involved in the clinical development of such inhibitors and their future potential applications in cancer medicine...
  52. ncbi request reprint A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies
    Gerhardt Attard
    The Institute of Cancer Research, Surrey, UK
    Prostate 69:1507-20. 2009
    ..New in vitro models of castration-resistant prostate cancer (CRPC) are urgently required...
  53. doi request reprint Development of therapeutic combinations targeting major cancer signaling pathways
    Timothy A Yap
    Royal Marsden National Health Service Foundation Trust and the Institute of Cancer Research, Sutton, Surrey, United Kingdom
    J Clin Oncol 31:1592-605. 2013
    ..Although considerable challenges remain, these efforts may enable important steps to be taken toward more durable therapeutic control of many cancers...
  54. doi request reprint Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer
    Roberta Ferraldeschi
    Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
    Clin Chem 59:75-84. 2013
    ....
  55. doi request reprint A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer
    Martijn P Lolkema
    Phase I Unit, Royal Marsden NHS Foundation Trust, Surrey and London, United Kingdom
    Clin Cancer Res 17:581-8. 2011
    ..We aimed to determine the safety and feasibility of combining reovirus administration with gemcitabine and to describe the effects of gemcitabine on the antireoviral immune response...
  56. doi request reprint Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients
    Gerhardt Attard
    Section of Medicine, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
    Clin Cancer Res 17:3867-75. 2011
    ..The use of biomarkers for patient selection, monitoring of treatment activity, and acceleration of drug approval will be critical for achieving further improvements in the treatment for CRPC, and is also discussed in detail...
  57. ncbi request reprint Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies
    Timothy A Yap
    Drug Development Unit, Royal Marsden NHS Foundation Trust, Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5PT, UK
    Expert Opin Investig Drugs 20:1293-304. 2011
    ..Such evidence has led to the design and conduct of drug development programs targeting the IGF-I receptor (IGF-IR) over the past 10 years...
  58. doi request reprint The CT flare response of metastatic bone disease in prostate cancer
    Christina Messiou
    Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK
    Acta Radiol 52:557-61. 2011
    ..The appearance of new or worsening bone sclerosis on CT in patients with prostate cancer may therefore be erroneously classified as disease progression...
  59. pmc Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
    David Olmos
    The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK
    Lancet Oncol 11:129-35. 2010
    ..Preclinical data suggest a dependence on insulin-like growth-factor signalling for sarcoma subtypes, including Ewing's sarcoma, and early reports show antitumour activity of IGF-1R-targeting drugs in these diseases...
  60. ncbi request reprint Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer
    Gerhardt Attard
    Institute for Cancer Research The Royal Marsden NHS Foundation Trust, Centre for Cancer Therapeutics, Sutton, Surrey, UK
    BJU Int 96:1241-6. 2005
  61. doi request reprint Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100
    Juliet Richards
    Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 72:2176-82. 2012
    ..Together, our findings provide a strong rationale for clinical evaluation of combined CYP17A1 inhibition and AR antagonism...
  62. doi request reprint Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises
    Timothy A Yap
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
    Curr Opin Pharmacol 8:393-412. 2008
    ..Finally, we discuss the issues and limitations involved with targeting the PI3K-AKT-mTOR pathway, and predict what the future may hold for these novel anticancer therapeutics...
  63. doi request reprint Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
    L Rhoda Molife
    Drug Development Unit, Divisions of Cancer Therapeutics and Clinical Sciences, Institute of Cancer Research Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
    Future Oncol 10:219-31. 2014
    ..The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients...
  64. doi request reprint First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors
    Timothy A Yap
    Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 29:4688-95. 2011
    ..A phase I study of MK-2206 was conducted to investigate its safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics (PDs), and preliminary antitumor efficacy...
  65. doi request reprint PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer
    Bristi Basu
    Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Drugs 72:1579-90. 2012
    ..Development of robust predictive biomarkers of response for optimal patient selection and rational combination strategies must be pursued if the full potential of these agents is to be realized...
  66. doi request reprint Belinostat: clinical applications in solid tumors and lymphoma
    L Rhoda Molife
    Drug Development Unit, Division of Clinical Sciences, The Institute of Cancer Research The Royal Marsden, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Expert Opin Investig Drugs 20:1723-32. 2011
    ..Belinostat is one member of the class that has been tested as a single agent and in combination with other chemotherapies and biological agents in the treatment of solid tumors and lymphoma...
  67. ncbi request reprint CYP17 inhibition as a hormonal strategy for prostate cancer
    Alison Hm Reid
    Institute of Cancer Research and the Royal Marsden Hospital, Surrey, UK
    Nat Clin Pract Urol 5:610-20. 2008
    ..The rationale for and implications of CYP17 inhibition and the CYP17-targeting agents in development are discussed in this Review...
  68. pmc New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway
    Gerhardt Attard
    Section of Medicine, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
    Clin Cancer Res 17:1649-57. 2011
    ....
  69. ncbi request reprint HGF/c-MET targeted therapeutics: novel strategies for cancer medicine
    Timothy A Yap
    Royal Marsden NHS Foundation Trust and The Institute of Cancer Research Downs Road, Sutton, Surrey, United Kingdom
    Curr Drug Targets 12:2045-58. 2011
    ..This review focuses on the underlying oncogenic role of aberrant HGF/c-MET signaling in malignant progression, as well as recent preclinical and clinical data on the different strategies employed in inhibiting HGF/c-MET function...
  70. pmc Revisiting the role of antiandrogen strategies in ovarian cancer
    Dionysis Papadatos-Pastos
    Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
    Oncologist 16:1413-21. 2011
    ..A specific example is the new agent abiraterone. In addition, we propose a panel of molecules that could be assessed as potential biomarkers that may aid patient selection for this approach in the future...
  71. doi request reprint Horizon scanning for novel therapeutics for the treatment of prostate cancer
    Diletta Bianchini
    The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Section of Medicine, Drug Development Unit, Downs Road, Sutton, Surrey SM2 5PT, UK
    Expert Opin Investig Drugs 19:1487-502. 2010
    ..Improved understanding of the underlying molecular drivers of prostate cancer pathogenesis, progression and resistance development has provided the fundamental basis for rational targeted drug design...
  72. ncbi request reprint A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors
    Alison H M Reid
    The Royal Marsden Hospital NHS Foundation Trust, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Clin Cancer Res 15:4978-85. 2009
    ....
  73. ncbi request reprint Early oncology clinical trial design in the era of molecular-targeted agents
    Andre T Brunetto
    Section of Medicine, The Institute of Cancer Research, Drug Development Unit, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Future Oncol 6:1339-52. 2010
    ....
  74. doi request reprint FGF receptor inhibitors: role in cancer therapy
    Gennaro Daniele
    Drug Development Unit, Division of Cancer Therapeutics, The Institute of Cancer Research The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Curr Oncol Rep 14:111-9. 2012
    ..This review will summarize the current clinical status of agents targeting FGF receptors. In addition, strategies to accelerate the clinical development of these targeted agents will be presented...
  75. ncbi request reprint A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
    Debashis Sarker
    Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom
    Clin Cancer Res 14:2075-81. 2008
    ..To determine the maximum tolerated dose (MTD) dose-limiting toxicity, and pharmacokinetic and pharmacodynamic profile of TKI258 (formerly CHIR-258)...
  76. ncbi request reprint A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies
    Chooi P Lee
    Royal Marsden Hospital, Sutton, United Kingdom
    Clin Cancer Res 12:2841-8. 2006
    ..To investigate the safety, tolerability, and pharmacokinetic profile of the novel nucleoside analogue OSI-7836 in patients with advanced solid malignancies...
  77. doi request reprint Abiraterone acetate: redefining hormone treatment for advanced prostate cancer
    Carmel J Pezaro
    Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
    Drug Discov Today 17:221-6. 2012
    ..This paper will review the preclinical discovery and clinical development of AA and will outline the strategy of parallel translational research...
  78. doi request reprint Utilizing circulating tumor cells: challenges and pitfalls
    Gerhardt Attard
    Section of Medicine, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK
    Curr Opin Genet Dev 21:50-8. 2011
    ....
  79. doi request reprint Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy
    Katie Twigger
    The Institute of Cancer Research, Targeted Therapy Laboratory, Cancer Research UK Centre for Cell and Molecular Biology, Chester Beatty Laboratories, London, United Kingdom
    Clin Cancer Res 14:912-23. 2008
    ..To test combination treatment schedules of reovirus and radiation in human and murine tumor cells in vitro and in vivo...
  80. pmc Future directions in the evaluation of c-MET-driven malignancies
    Johann S de Bono
    Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK
    Ther Adv Med Oncol 3:S51-60. 2011
    ..This paper discusses these issues, with a particular focus on future directions in the evaluation of c-MET-driven malignancies...